仑伐替尼联合帕博利珠单抗治疗晚期复发性子宫内膜癌的成本效果分析
本研究构建决策分析模型,评估仑伐替尼联合帕博利珠单抗(LP)相比多柔比星、聚乙二醇脂质体多柔比星(PLD)和贝伐珠单抗在微卫星稳定(MSS)复发性经治子宫内膜癌(EC)患者中的成本效果。结果显示LP每周期联合药物成本需从超过58,000美元降至低于11,000美元才具成本效果。结论认为LP在该人群中不具成本效果。
要点
- LP每周期联合药物成本需降至低于11,000美元才具成本效果。
核心结论
- 在复发性经治MSS子宫内膜癌患者中,仑伐替尼联合帕博利珠单抗不具成本效果。
- 需大幅降低LP的药物成本才能使其具有成本效果。
研究设计与样本
- 决策分析模型,评估LP相对于多柔比星、PLD和贝伐珠单抗的成本效果。
- 使用已发表数据估算QALY,药物成本采用平均批发价格。
- 对LP组应用-0.10的健康状态效用(HSU)惩罚以反映治疗毒性。
- 支付意愿阈值设为10万美元/QALY。
主要发现
- 敏感性分析显示,若LP每周期联合药物成本从超过58,000美元降至低于11,000美元,则具成本效果。
关键数值与推荐
- 支付意愿阈值:10万美元/QALY。
- LP每周期联合药物成本需低于11,000美元才具成本效果。
临床怎么用
- 对于复发性经治MSS子宫内膜癌患者,选择LP方案时需考虑其极高的经济负担。
- 在药物价格未大幅下降前,LP相对于标准化疗不具经济性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the cost-effectiveness of lenvatinib plus pembrolizumab (LP) in patients with microsatellite stable (MSS), recurrent, pretreated endometrial cancer (EC). METHODS: A decision analysis model was created to evaluate the cost-effectiveness of LP relative to doxorubicin, pegylated liposomal doxorubicin (PLD), and bevacizumab in patients with recurrent pretreated MSS EC. Published data was used to estimate quality adjusted life years (QALYs) and drug cost estimates were obtained using average wholesale prices. A health state utility (HSU) penalty of -0.10 was applied to the LP group to account for treatment toxicity. Incremental cost-effectiveness ratios (ICERs) were calculated to determine cost/QALY. The willingness to pay threshold (WTP) was set at $100,000 per QALY saved. Sensitivity analyses were performed on cost, effectiveness, and HSU penalty for LP. RESULTS: Costs of treatment with doxorubicin, PLD, and bevacizumab are $23.7 million (M), $56.9 M, and $250.8 M respectively. Cost of treatment with LP is $1.8 billion. Relative to doxorubicin, the ICERs for PLD, bevacizumab, and LP are $56,808, $345,824, and $1.6 M respectively. A sensitivity analysis varying the cost of LP shows that if the combined drug cost decreases from over $58,000 to less than $11,000 per cycle, this strategy would be cost-effective. Eliminating the HSU penalty for LP decreased the ICER $1.0 M while increasing the penalty to -0.20 increased the ICER to $3.7 M. CONCLUSIONS: LP is not cost-effective in patients with recurrent pretreated, MSS EC. A dramatic reduction in cost of LP is required for this novel strategy to be cost-effective.
引用
- Barrington DA, Haight PJ, Calhoun C, et al. Lenvatinib plus pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis. Gynecol Oncol. 2021. PMID: 34148720. doi:10.1016/j.ygyno.2021.06.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。